Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Clinical Pharmacokinetics of Vemurafenib in BRAF-Mutated Melanoma Patients.

Journal of clinical pharmacology - 1 Jan 2017

Nijenhuis C M, Huitema A D R, Blank C, Haanen J B A G, van Thienen J V, Rosing H, Schellens J H M, Beijnen J H

Abstract excerpt

No abstract is available from the source.

Topics

Join the communities discussing this publication.

Aged, 80 and over
Antineoplastic Agents
Indoles
Melanoma
Proto-Oncogene Proteins B-raf
Skin Neoplasms
Sulfonamides

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 27365214
DOI: 10.1002/jcph.788

Genes

BRAF

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

0

discussions

0

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Clinical Pharmacokinetics of Vemurafenib in BRAF-Mutated Melanoma Patients.PMID 27365214Read ↗

Vemurafenib in Chinese patients with BRAFV600 mutation-positive unresectable or metastatic melanoma: an open-label, multicenter phase I study.Semantic proximity Read ↗

FDA approves vemurafenib for treatment of metastatic melanoma.Semantic proximity Read ↗

Vemurafenib in patients with BRAF V600E mutation-positive advanced melanoma.Semantic proximity Read ↗

Vemurafenib for the treatment of BRAF mutant metastatic melanoma.Semantic proximity Read ↗

Community experience of vemurafenib for BRAF(V600) melanoma.Semantic proximity Read ↗

Vemurafenib: an evidence-based review of its clinical utility in the treatment of metastatic melanoma.Semantic proximity Read ↗

Vemurafenib in patients with BRAF(V600) mutated metastatic melanoma: an open-label, multicentre, safety study.Semantic proximity Read ↗

Vemurafenib therapy for stage IV melanoma with V600G-mutation.Semantic proximity Read ↗

Vemurafenib: the road to personalized medicine in melanoma.Semantic proximity Read ↗

Vemurafenib: a new treatment for BRAF-V600 mutated advanced melanomaSemantic proximity Read ↗

Targeted inhibition of the BRAF pathway in a patient with stage IV melanoma.Semantic proximity Read ↗

BRAF(V600) mutation levels predict response to vemurafenib in metastatic melanoma.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.